Josep Carreras Leukaemia Research Institute

A CXCR4-Targeted Dual-Acting Nanoconjugate Combines Protein-Toxin and Small-Molecule Warheads for Synergistic Cytotoxicity

Abstract Self-assembling multivalent protein nanoparticles with an architecture based on His-metal coordination and specific binding to cancer stem cells have emerged as promising tools for the selective delivery of microbial toxins in oncology, reaching precise cytotoxic effects...

Incidence trends and five-year survival of multiple myeloma and other plasma cell neoplasms in Girona, Spain: a population-based study, 1994–2020

Abstract Multiple myeloma is the most common malignant tumor originating in plasma cells. Its incidence varies across populations according to demographic and environmental factors, although its exact etiology remains unclear; reports on survival and advances in treatment are lac...

Astrocytic PI3Kα controls synaptic plasticity and cognitive function via serine metabolism

Astrocytes modulate neuronal activity by gliotransmission and through metabolic regulation, yet the relationship between these functions remains poorly understood. Here we show that phosphatidylinositol 3-kinase (PI3K) signaling in astrocytes controls synaptic plasticity and memo...

Talquetamab for people living with relapsed/ refractory multiple myeloma: plain language summary of the MonumenTAL-1 study

Plain Language SummaryWhat is this summary about?This summary describes how well talquetamab worked and its safety at a median (midpoint) of 17–26 months follow-up from the MonumenTAL-1 study, which tested talquetamab treatment for a type of cancer called relapsed/refractory mult...

Tisa-cel and axi-cel CAR structure influences the development of resistance to CD19-CAR-T therapy

CD19-CAR-T cells are a major therapy for relapsed/refractory B-cell malignancies, yet ~50% of patients relapse after infusion. Clinical data suggest that tisa-cel treatment is associated with higher rates of CD19 mutation than axi-cel, though direct comparisons have been lacking....

Anticancer effects of an XPO1 inhibitor (selinexor) with sotorasib following omeprazole preconditioning in KRAS G12C-mutant non-small cell lung cancer cells in vitro and in a mouse tumor xenograft

BACKGROUND: KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC) is currently treated with KRAS G12C covalent inhibitors, such as sotorasib, or RAS (ON) G12-selective inhibitors; however, response rates and progression-free survival remain limited, with recurrence occurri...

Elevated IL-10 is Linked With the Expansion of T-bethighCD21low B Cells in Patients With Common Variable Immunodeficiency

Abstract Common variable immunodeficiency (CVID) is frequently complicated by autoimmune and inflammatory manifestations associated with profound immune dysregulation (CVIDc), including expansion of T-bet high CD21 low B cells (CD21 low B cells). Elevated serum IL-10 levels have...

Treatment-free remission after bosutinib discontinuation (BOSUTFR): results from a multicenter real-world study by the Spanish CML group

Treatment-free remission (TFR) is an established therapeutic goal for patients with chronic myeloid leukemia (CML) achieving sustained deep molecular response (DMR) on tyrosine kinase inhibitors (TKIs). However, evidence on TFR following bosutinib discontinuation remains limited....